CG214

CG214 is a preclinical-stage small molecule inhibitor developed by ConverGene as part of its CVG101 program. It is designed as a dual-acting agent that targets both the Bromodomain and Extra-Terminal (BET) family of proteins (including BRD2, BRD3, BRD4, and BRDT) and the Dopamine Receptor D2 (DRD2). By inhibiting BET proteins, CG214 disrupts the transcription of key oncogenic drivers such as MYC, while its antagonism of DRD2 is intended to enhance anti-tumor efficacy through a distinct but complementary pathway. The compound was featured in a 2017 AACR poster presentation demonstrating its potency in various cancer models, including hematologic malignancies and solid tumors. Although other candidates within the CVG101 program, such as CG223, have been prioritized for IND-enabling studies, CG214 remains a characterized lead compound in ConverGene's epigenetic modulator portfolio.